Ultime notizie per Mesoblast (NASDAQ:MESO) Azioni

Mesoblast

Mesoblast Ltd is a biotechnology company. It uses its proprietary technology platform to develop and commercialize allogeneic cellular medicines to treat complex diseases resistant to conventional standards of care and where inflammation plays a central role. The company's product candidates include; Ryoncil (remestemcel-L) for the treatment of steroid refractory acute graft versus host disease as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of cell technology platform for commercialization.

Mesoblast Limited - American Depositary Shares

Mesoblast Ltd

Meso Numismatics Inc

WISeKey PKI and SEALSQ Post-Quantum Technologies Enhance E-Voting Security through Advanced Cybersecurity and AI Integration

News

LAES

WKEY

WISeKey PKI and SEALSQ Post-Quantum Technologies Unveil New Phase In E-Voting Security With Advanced Cybersecurity And AI Integration

Contracts

Founder Group's Founder Energy Sdn Bhd Subsidiary Receives $3.8M New Solar EPCC Photovoltaic Contract

Macro Economic Events

Econ #s

Economics

Private Nonfarm Payrolls For Oct. Prior Revised From 223K To 192K

Canaccord Genuity analyst Susan Anderson maintains Estee Lauder Cos (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EL#NYSE">EL</a>) with a Hold and lowers the price target from $100 to $75.

Price Target

Analyst Ratings

Canaccord Genuity Maintains Hold on Estee Lauder Cos, Lowers Price Target to $75

Biotech

General

SeaStar Medical Reports New Monthly Enrollment Record With 10 Critically Ill Acute Kidney Injury Patients Added To NEUTRALIZE-AKI Pivotal Trial

Private Nonfarm Payrolls For Oct. -28K Vs 90K Expected, 223K Prior

Macro Notification

USA Nonfarm Payrolls For October 12K Vs 106K Est.; 223K Prior

Average Hourly Earnings Month Over Month (Oct) +0.4% vs +0.3% Est.

USA Unemployment Rate For October 4.1% Vs 4.1% Est.; 4.1% Prior

BHP (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BHP#NYSE">BHP</a>) has backtracked on remarks by its Chairman, Ken Mackenzie, about "moving on "from its <a target="_blank" href="https://www.benzinga.com/news/large-cap/24/05/39068033/time-runs-out-for-bhp-deal-49-billion-acquisition-of-anglo-american-proves-too-complex-to-solve" rel="noreferrer noopener">failed $49 billion bid</a> for Anglo American (OTCQX:<a class="ticker" href="https://www.benzinga.com/stock/AAUKF#OTCQX">AAUKF</a>).
During BHP's annual shareholder meeting in Brisbane, MacKenzie had suggested that the Anglo American acquisition was a "nice to have, not a must-do" and indicated that BHP had put the deal behind them, <a target="_blank" href="https://www.theguardian.com/business/2024/oct/30/mining-firm-bhp-says-it-has-moved-on-from-failed-anglo-american-bid" rel="noreferrer noopener">reported</a> The Guardian.
"We thought there was an opportunity here to create something unique and special&#8230; But Anglo American shareholders had a different view, and so they moved on. And quite frankly, so have we," he stated.
However, BHP issued a <a target="_blank" href="https://www.bhp.com/news/media-centre/releases/2024/10/statement-regarding-anglo-american-plc" rel="noreferrer noopener">statement</a> clarifying that these comments were not intended to be a formal withdrawal from pursuing the deal under U.K. takeover regulations.
Following a discussion with the U.K. Takeover Panel, BHP confirmed that the panel would not treat MacKenzie's remarks as an official "no offer" statement, meaning the door remains open for a potential future bid.
Initially <a target="_blank" href="https://www.benzinga.com/markets/equities/24/04/38423994/worlds-largest-miner-bhp-bids-to-takeover-anglo-american-as-hunt-for-resources-intensify" rel="noreferrer noopener">proposed in April</a>, BHP's bid for Anglo American sought access to Anglo's lucrative copper assets in South America – as the price for the metal crucial in the green energy transition surged toward its <a target="_blank" href="https://www.benzinga.com/economics/macro-economic-events/24/05/38901984/silver-rockets-to-11-year-highs-copper-hits-record-peak-gold-approaches-historic-" rel="noreferrer noopener">yearly high in May</a>.
Despite the strategic fit, the deal faced hurdles, particularly concerning Anglo's South African assets. BHP hesitated to retain those due to regulatory complexities and economic risks associated with South Africa's business environment.
Unable to secure the deal, BHP turned to its key assets, looking to expand its Olympic Dam operation in South Australia and the Escondida mine in Chile; however, their domestic operations face challenges that could drive higher costs.
Australia's mining industry has been grappling with high labor expenses as worker shortages and competition drive wages upward. New labor laws, including the "Same Job, Same Pay" initiative, have raised concerns over their potential to <a target="_blank" href="https://www.benzinga.com/news/large-cap/24/07/39647424/bhp-cuts-employee-incentives-misses-performance-goals" rel="noreferrer noopener">increase operational costs</a>.&nbsp;
At the Brisbane meeting, labor issues were a key focus, with hundreds of workers protesting BHP's stance on the new legislation and its effect on profitability.
Still, the company managed to increase its footprint in South America. In July, it <a target="_blank" href="https://www.benzinga.com/markets/equities/24/07/40031488/bhp-to-unlock-south-american-copper-riches-partners-with-lundin-for-filo-acquisition" rel="noreferrer noopener">announced a bid</a> for Filo Corp (OTCQX:<a class="ticker" href="https://www.benzinga.com/stock/FLMMF#OTCQX">FLMMF</a>). Through a 50-50 joint venture with Lundin Mining (OTC:<a class="ticker" href="https://www.benzinga.com/stock/LUNMF#OTC">LUNMF</a>), BHP will spend $2 billion to acquire a 50% stake in the promising Filo del Sol copper project on the Chilean-Argentine border and a 50% stake in Lundin's Josemaria project.
The mandatory standstill on a new bid for Anglo American expires on November 29.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/economics/macro-economic-events/24/10/41663633/biggest-gold-etf-posts-highest-monthly-inflows-in-2-5-years-as-investors-rush-to-" target="_blank" rel="noreferrer noopener">Biggest Gold ETF Posts Highest Monthly Inflows In 2.5 Years As Investors Rush To Safe Haven Ahead Of Presidential Election</a></li>
</ul>
Photo via Shutterstock

Large Cap

Commodities

Legal

AAUKF

FLMMF

LUNMF

BHP Backtracks Its Comments On Abandoning Anglo American Deal

Canaccord Genuity analyst Brian McNamara maintains Driven Brands Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DRVN#NASDAQ">DRVN</a>) with a Buy and raises the price target from $20 to $21.

DRVN

Canaccord Genuity Maintains Buy on Driven Brands Hldgs, Raises Price Target to $21

JMP Securities analyst John Colantuoni maintains Booking Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BKNG#NASDAQ">BKNG</a>) with a Market Outperform and raises the price target from $5000 to $5400.

BKNG

JMP Securities Maintains Market Outperform on Booking Holdings, Raises Price Target to $5400

Earnings

Global Engine Group FY24 EPS $0.021; Revenue $6.33M

Canaccord Genuity analyst Whitney Ijem maintains Alnylam Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) with a Buy and raises the price target from $366 to $384.

ALNY

Canaccord Genuity Maintains Buy on Alnylam Pharmaceuticals, Raises Price Target to $384

S&amp;W Seed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SANW#NASDAQ">SANW</a>) reported quarterly losses of $(2.95) per share which missed the analyst consensus estimate of $(1.90) by 55.26 percent. This is a 2169.23 percent decrease over losses of $(0.13) per share from the same period last year. The company reported quarterly sales of $14.82 million which missed the analyst consensus estimate of $23.00 million by 35.57 percent. This is a 35.72 percent decrease over sales of $23.05 million the same period last year.

Earnings Misses

SANW

S&W Seed Q4 Adj $(2.95) Misses $(1.90) Estimate, Sales $14.82M Miss $23.00M Estimate

Friday,&nbsp;Cardinal Health Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAH#NYSE">CAH</a>) reported first-quarter 2025 adjusted EPS of $1.88, up 9% year over year, beating the&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus of $1.62</a>.
Sales decreased 4% to $52.28 billion, beating the&nbsp;consensus of $50.90 billion. Adjusted operating earnings increased 12% to&nbsp;$625 million.
First-quarter revenue for the Pharmaceutical and Specialty Solutions segment decreased by 5% to&nbsp;$48.0 billion. Excluding the customer contract expiration, revenue increased by 16%, driven by brand and specialty pharmaceutical sales growth <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/n41679244/cardinal-health-reports-first-quarter-fiscal-year-2025-results-and-raises-fiscal-year-2025-outlook" rel="noreferrer noopener">from existing customers</a>.
Pharmaceutical and Specialty Solutions segment profit increased 16% to&nbsp;$530 million, driven by a higher contribution from brand and specialty products, including the earlier seasonal launch of COVID-19 vaccine distribution and positive generics program performance.
The Pharmaceutical and Specialty Solutions segment distributes branded and generic pharmaceuticals, specialty drugs, and OTC products and offers services for specialty pharmaceuticals, supporting both manufacturers and healthcare providers and pharmacy management services.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/large-cap/24/09/40694838/opioid-settlement-drug-distributors-mckesson-cencora-cardinal-health-to-pay-300m-to-health-insurer" rel="noreferrer noopener">Opioid Settlement: Drug Distributors McKesson, Cencora, Cardinal Health To Pay $300M To Health Insurers</a>
Revenue for the Global Medical Products and Distribution segment increased 3% to&nbsp;$3.1 billion, driven by volume growth from existing customers.
Global Medical Products and Distribution (GMPD) segment profit decreased to&nbsp;$8 million, primarily due to higher manufacturing and health and welfare costs, largely offset by improved net inflationary impacts, including mitigation initiatives and growth from existing customers.
GMPD segment manufactures, sources, and distributes Cardinal Health brand medical, surgical, and laboratory products, as well as distributes medical, surgical and laboratory products known as national brand products
&#8220;We began fiscal 2025 by delivering strong operational and financial performance, led by the Pharmaceutical and Specialty Solutions segment,&#8221; said&nbsp;Jason Hollar, CEO of Cardinal Health.
&#8220;The strength and resiliency of our largest and most significant business continues to shine, giving us confidence to raise our fiscal 2025 enterprise guidance only a quarter into the year,&#8221; Hollar added.
Outlook:&nbsp;Cardinal Health has raised its fiscal year 2025 outlook for adjusted EPS to $7.75-$7.90 from <a target="_blank" href="https://www.benzinga.com/news/earnings/24/08/40364087/pharma-distribution-giant-cardinal-health-lifts-2025-guidance-after-q4-earnings-beat-raises-stock-b" rel="noreferrer noopener">prior guidance of</a> $7.55-$7.70 versus consensus of $7.63.
The guidance includes an update to the company&#8217;s Pharmaceutical and Specialty Solutions segment profit outlook to 4% to 6% growth, from 1% to 3% growth.
The company also updated its Global Medical Products and Distribution segment profit outlook to&nbsp;$140 million&nbsp;to&nbsp;$175 million, from approximately&nbsp;$175 million, primarily due to the impact of higher health and welfare costs.
Additionally, the company updated expectations for its adjusted free cash flow to&nbsp;$1.0 billion&nbsp;to&nbsp;$1.5 billion, from approximately&nbsp;$1.0 billion.
Price Action: CAH stock is trading 2.97% higher at $111.74 during the premarket session at last check Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/10/41661764/ford-to-halt-f-150-ev-production-for-7-weeks-next-month" target="_blank" rel="noreferrer noopener">Ford To Halt F-150 EV Production For 7 Weeks Next Month</a></li>
</ul>
Photo via Company

Guidance

Health Care

Movers

Cardinal Health Raises 2025 Profit Outlook Again, Helped By Strong Drug Distribution Business

JMP Securities analyst Jason Butler maintains argenx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARGX#NASDAQ">ARGX</a>) with a Market Outperform and raises the price target from $497 to $606.

ARGX

JMP Securities Maintains Market Outperform on argenx, Raises Price Target to $606

Exxon Mobil Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XOM#NYSE">XOM</a>) shares are trading higher after the company reported&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/b41679046/exxonmobil-announces-third-quarter-2024-results" rel="noreferrer noopener">third-quarter&nbsp;results</a>.&nbsp;
Total revenues and other income&nbsp;stood at&nbsp;$90.016 billion, missing the consensus of&nbsp;$93.938 billion.
Net production stood at 4,582 thousand oil-equivalent barrels per&nbsp;day, an increase of&nbsp;5%&nbsp;from the previous quarter, driven by increased volumes from Pioneer assets.
Read: <a target="_blank" href="https://www.benzinga.com/news/24/10/41659147/exxon-mobil-q3-preview-will-rising-production-cost-cuts-boost-earnings" rel="noreferrer noopener">Exxon Mobil Q3 Preview: Will Rising Production, Cost Cuts Boost Earnings?</a>
Adjusted net profit came in at&nbsp;$8.61 billion, down from&nbsp;$9.24 billion in the prior quarter. Adjusted EPS stood at&nbsp;$1.92,&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">beating the consensus of&nbsp;$1.88</a>.
Exxon&#8217;s&nbsp;capital and exploration expenditures stood at&nbsp;$7.16 billion in the&nbsp;third quarter, bringing year-to-date 2024 expenditures to&nbsp;$20 billion, in line with the <a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener">company&#8217;s full-year&nbsp;guidance&nbsp;of&nbsp;$28 billion.</a>
This month, ExxonMobil and HELLEniQ ENERGY completed Phase 1 of offshore Crete exploration,<a target="_blank" href="https://www.benzinga.com/markets/equities/24/10/41270873/exxonmobil-helleniq-energy-jv-completes-first-exploration-phase-in-crete-eyes-next-steps" rel="noreferrer noopener"> gathering 7,789 km of seismic data</a>.
Cost Reduction: The company achieved a cumulative structural cost savings of&nbsp;$11.3&nbsp; billion versus 2019, including an additional&nbsp;$1.6 billion&nbsp;of savings during the year and&nbsp;$0.6 billion&nbsp;during the quarter.
The company plans to deliver cumulative savings totaling&nbsp;$15 billion&nbsp;through the end of 2027 versus 2019.
Dividend Boost: Exxon raised its dividend per share by 4% to $0.99 from&nbsp;$0.95 per share, payable on December 10, to shareholders of record as of November 14.
The company&#8217;s year-to-date shareholder distributions totaled $26.1 billion, comprising $12.3 billion in dividends and $13.8 billion in share repurchases.
Darren Woods, chairman and chief executive officer, said, &#8220;Our industry-leading results continue to demonstrate how our enterprise-wide transformation is improving the structural earnings power of the company.&#8221;
&#8220;In the Upstream, we&#8217;ve doubled the profitability of the barrels we produce on a constant price basis. In Product Solutions, we&#8217;ve high-graded our refining footprint and increased high-value product sales.&#8221;
Investors can gain exposure to XOM via&nbsp;EA Series Trust Strive U.S. Energy ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DRLL#NYSE">DRLL</a>) and&nbsp;SPDR Select Sector Fund – Energy Select Sector&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLE#NYSE">XLE</a>).
Price Action: XOM shares are up 2.07% at $119.20 premarket at the last check Friday.
Photo: Del Henderson Jr. via Shutterstock
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/10/41553999/exxon-mobils-golden-pass-lng-plant-gets-3-year-extension-amid-contractor-challenges-report" target="_blank" rel="noreferrer noopener">Exxon Mobil&#8217;s Golden Pass LNG Plant Gets 3-Year Extension Amid Contractor Challenges: Report</a></li>
</ul>

Equities

DRLL

Exxon Q3 Earnings: $11.3 Billion Cost Savings, Rising Production, Dividend Hike And More

Piper Sandler analyst Crispin Love maintains Blue Owl Cap (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OWL#NYSE">OWL</a>) with a Overweight and raises the price target from $23 to $25.

Piper Sandler Maintains Overweight on Blue Owl Cap, Raises Price Target to $25

JMP Securities analyst Nicholas Jones maintains Amazon.com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) with a Market Outperform and raises the price target from $265 to $285.

AMZN

JMP Securities Maintains Market Outperform on Amazon.com, Raises Price Target to $285

Mesoblast GAAP EPS of -$0.09 beats by $0.63, revenue of $5.9M misses by $1.71M

In a report released today, Edward Tenthoff from Piper Sandler reiterated a Buy rating on Mesoblast (MESO – Research Report), with a price target o...

Mesoblast (MESO) Receives a Buy from Piper Sandler

Bell Potter analyst John Hester maintained a Buy rating on Mesoblast Limited (MEOBF – Research Report) today and set a price target of A$1.40. The ...

Bell Potter Sticks to Their Buy Rating for Mesoblast Limited (MEOBF)

In a report released today, David Stanton from Jefferies upgraded Mesoblast Limited (MEOBF – Research Report) to a Buy, with a price target of A$1....

Mesoblast Limited (MEOBF) was upgraded to a Buy Rating at Jefferies

Mesoblast to issue $50M convertible notes for product launch

Mesoblast: Undervalued Due To Remestemcel-L's Substantial Growth Potential

Mesoblast (MESO) has released an update. Mesoblast Limited, a leader in cellular medicines, has announced a convertible note subscription agreement...

Mesoblast Secures $50M for RYONCIL Launch Prep

Hedge funds pile into healthcare stocks amid dip, Goldman Sachs says

Mesoblast (MESO) has released an update. Mesoblast Limited is making strides in advancing its late-stage pipeline of innovative cellular medicines ...

Mesoblast Advances Cellular Medicines Amid FDA Hopes

Analyst McCarthy holds two days of meetings with Founder & CEO Dr. Itescu and Head of Global Communications Hughes on October 21-22 hosted by Maxim...

Mesoblast management to meet with Maxim

AQST

AXGN

CDNA

CLOV

CRMD

JCRRF

MEOBF

MESO

PSNL

RMTI

Press Releases

Mesoblast to File Biologics License Application for Ryoncil® FDA Approval Next Week

Mesoblast Resubmits Biologics License Application (BLA) with United States Food & Drug Administration (FDA) for Approval of Ryoncil® in Children with Steroid-Refractory Acute Graft-Versus-Host Disease (SR-aGVHD)

Patient Enrollment Commenced in Pivotal Phase 3 Trial of Rexlemestrocel-L for Chronic Low Back Pain

FDA Accepts Mesoblast's Biologics License Application (BLA) for Ryoncil® in Children With Steroid-Refractory Acute Graft-Versus-Host Disease (SR-aGVHD)

Appendix 4C Quarterly Activity Report for Quarter Ended June 30, 2024

Mesoblast Financial Results and Corporate Update Webcast

Mesoblast Reports Financial Results and Operational Update for Fiscal Year Ended June 30, 2024

KaliVir Immunotherapeutics Appoints Schond Greenway as Chief Financial Officer

Mesoblast Option to Issue Up to US$50 Million Convertible Notes for Product Launch

Comments

Mesoblast

Notizie

Ultime notizie per Mesoblast (NASDAQ:MESO) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO